210 related articles for article (PubMed ID: 16103895)
1. Linking pathway gene expressions to the growth inhibition response from the National Cancer Institute's anticancer screen and drug mechanism of action.
Huang R; Wallqvist A; Thanki N; Covell DG
Pharmacogenomics J; 2005; 5(6):381-99. PubMed ID: 16103895
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of pathway or functionally related gene expression in the National Cancer Institute's anticancer screen.
Huang R; Wallqvist A; Covell DG
Genomics; 2006 Mar; 87(3):315-28. PubMed ID: 16386875
[TBL] [Abstract][Full Text] [Related]
3. A gene expression database for the molecular pharmacology of cancer.
Scherf U; Ross DT; Waltham M; Smith LH; Lee JK; Tanabe L; Kohn KW; Reinhold WC; Myers TG; Andrews DT; Scudiero DA; Eisen MB; Sausville EA; Pommier Y; Botstein D; Brown PO; Weinstein JN
Nat Genet; 2000 Mar; 24(3):236-44. PubMed ID: 10700175
[TBL] [Abstract][Full Text] [Related]
4. Linking the growth inhibition response from the National Cancer Institute's anticancer screen to gene expression levels and other molecular target data.
Wallqvist A; Rabow AA; Shoemaker RH; Sausville EA; Covell DG
Bioinformatics; 2003 Nov; 19(17):2212-24. PubMed ID: 14630650
[TBL] [Abstract][Full Text] [Related]
5. Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases.
Covell DG; Wallqvist A; Huang R; Thanki N; Rabow AA; Lu XJ
Proteins; 2005 May; 59(3):403-33. PubMed ID: 15778971
[TBL] [Abstract][Full Text] [Related]
6. Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
Huang R; Wallqvist A; Covell DG
J Med Chem; 2006 Mar; 49(6):1964-79. PubMed ID: 16539384
[TBL] [Abstract][Full Text] [Related]
7. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
[TBL] [Abstract][Full Text] [Related]
8. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action.
Huang R; Wallqvist A; Covell DG
Biochem Pharmacol; 2005 Apr; 69(7):1009-39. PubMed ID: 15763539
[TBL] [Abstract][Full Text] [Related]
9. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics.
Yamori T
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S74-9. PubMed ID: 12819939
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of the novel glutathione-activated thiopurine prodrugs cis-AVTP [cis-6-(2-acetylvinylthio)purine] and trans-AVTG [trans-6-(2-acetylvinylthio)guanine] results from the National Cancer Institute's anticancer drug screen.
Gunnarsdottir S; Elfarra AA
Drug Metab Dispos; 2004 Mar; 32(3):321-7. PubMed ID: 14977866
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data.
Blower PE; Yang C; Fligner MA; Verducci JS; Yu L; Richman S; Weinstein JN
Pharmacogenomics J; 2002; 2(4):259-71. PubMed ID: 12196914
[TBL] [Abstract][Full Text] [Related]
12. Web-based tools for mining the NCI databases for anticancer drug discovery.
Fang X; Shao L; Zhang H; Wang S
J Chem Inf Comput Sci; 2004; 44(1):249-57. PubMed ID: 14741034
[TBL] [Abstract][Full Text] [Related]
13. Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's Drug Discovery Program for Cancer and AIDS.
Weinstein JN; Myers T; Buolamwini J; Raghavan K; van Osdol W; Licht J; Viswanadhan VN; Kohn KW; Rubinstein LV; Koutsoukos AD
Stem Cells; 1994 Jan; 12(1):13-22. PubMed ID: 8142917
[TBL] [Abstract][Full Text] [Related]
14. Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure.
Keskin O; Bahar I; Jernigan RL; Beutler JA; Shoemaker RH; Sausville EA; Covell DG
Anticancer Drug Des; 2000 Apr; 15(2):79-98. PubMed ID: 10901296
[TBL] [Abstract][Full Text] [Related]
15. Molecular portrait of cisplatin induced response in human testis cancer cell lines based on gene expression profiles.
Duale N; Lindeman B; Komada M; Olsen AK; Andreassen A; Soderlund EJ; Brunborg G
Mol Cancer; 2007 Aug; 6():53. PubMed ID: 17711579
[TBL] [Abstract][Full Text] [Related]
16. Predicting drug response based on gene expression.
Robert J; Vekris A; Pourquier P; Bonnet J
Crit Rev Oncol Hematol; 2004 Sep; 51(3):205-27. PubMed ID: 15331079
[TBL] [Abstract][Full Text] [Related]
17. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors.
Wallqvist A; Huang R; Covell DG
J Chem Inf Model; 2007; 47(4):1414-27. PubMed ID: 17555311
[TBL] [Abstract][Full Text] [Related]
18. Differential gene expression as a potential classifier of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole-sensitive and -insensitive cell lines.
Wallqvist A; Connelly J; Sausville EA; Covell DG; Monks A
Mol Pharmacol; 2006 Mar; 69(3):737-48. PubMed ID: 16332985
[TBL] [Abstract][Full Text] [Related]
19. NCI's anticancer drug screening program may not be selecting for clinically active compounds.
Brown JM
Oncol Res; 1997; 9(5):213-5. PubMed ID: 9306428
[TBL] [Abstract][Full Text] [Related]
20. Gene expressions associated with chemosensitivity in human hepatoma cells.
Hoshida Y; Moriyama M; Otsuka M; Kato N; Taniguchi H; Shiratori Y; Seki N; Omata M
Hepatogastroenterology; 2007 Mar; 54(74):489-92. PubMed ID: 17523305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
